FDA approves first affordable biosimilar cancer drug

March 8, 2015 11:20 AM

13 0

The Food and Drugs Administration has moved to address increased concerns over the costs of cancer treatments by approving biosimilar drug, Zarxio, produced by Novartis Sandoz. The move by the agency moves to curtail a long running monopoly by some biotechnology companies, which have manufactured and sold expensive, complex medicines that have fewer less-expensive alternatives.

Zarxio is a drug that its developers hope will assist patients in forming white blood cells in cancer therapy. The drug should act as a substitute for the most costly treatments that usually leave a hole in cancer patient’s pockets. Some people are however arguing that it is a copy of an existing ...

Also read: FDA Approves First Nonopioid Treatment for Opioid Withdrawal Symptoms

Read more

To category page